Last reviewed · How we verify
Iodixanol 320 mgI/mL
Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and body cavities by absorbing X-rays.
Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and body cavities by absorbing X-rays. Used for Coronary and peripheral angiography, Urography and intravenous pyelography, Venography.
At a glance
| Generic name | Iodixanol 320 mgI/mL |
|---|---|
| Also known as | Visipaque |
| Sponsor | Guerbet |
| Drug class | Iso-osmolar contrast medium (IOCM) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Iodixanol contains iodine atoms that attenuate X-ray radiation, creating contrast in radiographic imaging. As an iso-osmolar contrast medium (IOCM), it has an osmolality equal to blood plasma, which may reduce nephrotoxicity and adverse reactions compared to hyperosmolar agents. It is used for angiographic and urographic procedures to visualize vascular and urinary anatomy.
Approved indications
- Coronary and peripheral angiography
- Urography and intravenous pyelography
- Venography
- Computed tomography (CT) imaging
Common side effects
- Contrast-induced nephropathy (CIN)
- Hypersensitivity reactions
- Nausea and vomiting
- Flushing and warmth sensation
- Renal impairment
Key clinical trials
- Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium
- A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease (PHASE4)
- A Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCT (NA)
- A Study of Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest Pain (NA)
- Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography (PHASE4)
- Pulmonary Interstitial Lymphography in Early Stage Lung Cancer (NA)
- Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |